Oscar Tahuahua, Medical Oncology Fellow at the National Cancer Institute of Mexico, shared a post on X:
“HER2DX and outcomes in early-stage HER2+ BC
A major step forward among 1,683 pts, 5-y iDFS was 97% (low-risk) vs 75% (high-risk); OS: 99% vs 89%
HER2DX provides independent prognostic stratification and may guide risk adapted escalation or de-escalation therapy.”
Title: HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.
Authors: Guillermo Villacampa, Tomás Pascual, Paolo Tarantino, Javier Cortés, José Perez-García, Antonio Llombart-Cussac, Pierfranco Conte, Mario Mancino, Valentina Guarneri, Maria Vittoria Dieci, Adrienne G Waks, Francesco Schettini, Fara Brasó-Maristany, Gaia Griguolo, Beatriz Alonso de Castro, Cristina Reboredo, Silvia Antolín, Coralia Bueno-Muiño, Isabel Echavarría, Sara López-Tarruella, Tatiana Massarrah, María del Monte-Millán, Miguel Martín, Wesley Buckingham, Joel S Parker, Ana Vivancos, Kornelia Polyak, Otto Metzger Filho, Antonio C Wolff, Angela DeMichele, Nadine M Tung, Charles M Perou, Laia Paré, Patricia Villagrasa, Aleix Prat, Sara M Tolaney
More posts featuring Oscar Tahuahua on OncoDaily.
